Introduction to Medexus Pharmaceuticals Offering
Medexus Pharmaceuticals Inc. has taken a significant step by launching an overnight marketed underwritten offering of common shares. This initiative is set to enhance the company's capital, supporting its future growth and operational strategies.
Details of the Offering
The offering is arranged through an underwriting agreement with Raymond James Ltd. acting as the lead underwriter. An over-allotment option is set, allowing underwriters to buy an additional 15% of the shares sold within 30 days post-closing. This strategic move demonstrates Medexus' proactive approach in ensuring financial flexibility.
Market Context and Timing
The final size and pricing of the Offering will be established based on market conditions. While the expected closing date is around January 31, 2025, it's essential to note that the offering's completion depends on several market conditions and customary closing requirements.
Use of Proceeds
Proceeds from the offering are earmarked for critical needs, including repaying a US$2.5 million credit from medac and funding ongoing business development activities. This allocation underscores Medexus' commitment to maintaining its growth trajectory while managing its financial obligations effectively.
Regulatory Aspects and Legal Considerations
The whole process will be governed by regulatory standards, including necessary approvals before the offering can proceed. The Company plans to file a prospectus supplement, ensuring completion of the required documentation by adhering to legal requirements.
About Medexus Pharmaceuticals
Medexus is not just a pharmaceutical company but a pioneering force in the specialty market. With a robust platform in North America, they focus on innovative solutions for rare diseases, particularly in areas such as oncology, hematology, and rheumatology.
Innovative Solutions for Rare Diseases
With a keen eye on developing treatment solutions, Medexus operates within niche therapeutic areas, actively pursuing advancements that may improve patient outcomes in areas like autoimmune diseases and dermatology. The commitment to innovation positions the company favorably amidst the competitive landscape.
Company Contacts
For inquiries about the offering or additional information regarding the company, please reach out to:
Ken d'Entremont | CEO, Medexus Pharmaceuticals
Tel: 905-676-0003 | Email: ken.dentremont@medexus.com
Brendon Buschman | CFO, Medexus Pharmaceuticals
Tel: 416-577-6216 | Email: brendon.buschman@medexus.com
Victoria Rutherford | Adelaide Capital
Tel: 480-625-5772 | Email: victoria@adcap.ca
Frequently Asked Questions
What is the purpose of the common shares offering?
The offering aims to generate capital to repay debts and support the company's ongoing strategic business development activities.
Who are the underwriters for this offering?
Raymond James Ltd. is acting as the lead underwriter for Medexus in this offering.
When is the expected closing date for the offering?
The closing of the offering is anticipated around January 31, 2025, depending on market and regulatory conditions.
Where can I find more information about Medexus?
Comprehensive details about Medexus and its offerings can be accessed through the company's corporate website and their profile on SEDAR+.
What are Medexus' primary therapeutic focuses?
The company primarily focuses on oncology, hematology, rheumatology, autoimmune diseases, and dermatology.
